Table 2 Literature review of patients receiving treatment combining omalizumab and other biological agents
From: Dual biological treatments in immune-mediated disorders: a single center experience
Molecular target of non-omalizumab biological agent | Non-IgE-targeting Monoclonal antibodies | N | Age (years) | Gender | Indication for Omalizumab/ dose | Non-IgE-targeting biologic indication/ dose | Period of Oma. (months) | Period of dual treatment (months) | Adverse reactions to both monoclonal antibodies | Dual treatment enabled tapering down CS (Baseline dose/follow-up dose) | F/U (months) | Ref. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
IL-5/IL-5Rα | Mepolizumab | 1 | 12 | F | Asthma/ 300 mg every 4 weeks | Asthma/ 100 mg every 4 weeks | 10 | 24 | None | Yes (NA) | 34 | [9] |
1 | 55 | F | Asthma/NA | Asthma/NA | 24 | 7 | None | Yes (20/4) | 11 | [10] | ||
1 | 58 | F | ABPA/ 300 mg every 2 weeks | ABPA/100 mg every 4 weeks | 8 | 15 | None | Yes (1 mg/kg /0 mg) | 15 | [11] | ||
12* | 12–73 | 6 F 6 M | Asthma/225–300 mg every 4 weeks (n = 6) ABPA/375 mg every 4 weeks (n = 2) CSU/NA (n = 1) CRSwNP/300 mg every 4 weeks (n = 1) Non-specific inflammatory lung disease/375 mg every 4 weeks (n = 1) | EGPA/100 mg every 4 weeks (n = 1) Asthma/300 mg every 4 weeks (n = 7) ABPA/100 mg every 4 weeks (n = 2) HES/300 mg every 4 weeks (n = 1) Non-specific inflammatory lung disease/100 mg every 4 weeks (n = 1) | 6–72 | 1–48 | None | NA | NA | [12] | ||
1 | 68 | F | Asthma/300 mg every 4 weeks | Asthma/ 100 mg every 4 weeks | 108 | 36 | None | Yes (25/20) | 144 | [13] | ||
1 | 51 | M | CSU/ 300 mg every 4 weeks | Asthma/ 100 mg every 4 weeks | 6 months with mepolizumab monotherapy | 6 | None | Yes (30/0) | 12 | [14] | ||
1** | 53 | M | Asthma/450 every 4 weeks | Asthma/30 mg every 4 weeks | 29 | 18 | None | Asthma is controlled (NA) | 11 years | [15] | ||
1 | 55 | F | Asthma/300 mg every 4 weeks | Asthma/ 100 mg every 4 weeks | 12 months omalizumab monotherapy. 14 months mepolizumab monotherapy | 24 | None | Yes (20/2.5) | 50 | [16] | ||
Benralizumab | 4 | 27–53 | 3 F 1 M | Asthma/150–450 every 4 weeks (n = 4) | Asthma/30 mg every 4 weeks (n = 4) | NA | 3–36 | None | NA | NA | [12] | |
CD20 | Rituximab | 17 | 47–88 | 8 M 9 F | Bullous pemphigoid | Bullous pemphigoid | NA | NA | None | NA | NA | [17] |
TNFα | Etanercept | 1 | 64 | F | CSU/ 300 mg every 4 weeks | RA/ 50 mg every 2 weeks | 3 | None | NA | NA | [7] | |
Adalimumab | 1 | 21 | F | CSU/300 mg every 4 weeks for 6 months | psoriatic arthritis/40 mg every week | 6 | 6 | None | NA | 18 | [18] | |
IL-17 | Secukinumab | 1 | 58 | F | CSU/300 mg every 4 weeks | chronic refractory psoriasis vulgaris/ loading dose 300 mg /week for 4 weeks followed by maintenance dose of 300 mg every 4 weeks | 1 | 18 | None | NA | 20 | [19] |
IL-23 | Guselkumab | 1 | 57 | M | CSU/NA | psoriasis vulgaris/ NA | 9 years | 21 | None | NA | 129 | [8] |
IL-4/IL-13 Rα | Dupilumab | 1 | 70 | M | Bullous pemphigoid/ 300 mg every 4 weeks | Bullous pemphigoid/ first dose 600 mg followed by 300 mg every week | 2 | 10 | None | Yes (NA/0) | 10 | [20] |
6 | 26–63 | 4 F 2 M | CSU/ 125–300 mg every 4 weeks (n = 5) APBA/ 375 mg every 2 weeks (n = 1) | AD/ 300 mg every 2 weeks (n = 3) ABPA/300 mg every 2 weeks (n = 1) CSU/300 mg every 2 weeks (n = 2) | 3–16 | 2–24 | None | NA | NA | [12] |